Your browser doesn't support javascript.
loading
Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis.
Roos, Izanne; Sharmin, Sifat; Malpas, Charles; Ozakbas, Serkan; Lechner-Scott, Jeannette; Hodgkinson, Suzanne; Alroughani, Raed; Eichau Madueño, Sara; Boz, Cavit; van der Walt, Anneke; Butzkueven, Helmut; Buzzard, Katherine; Skibina, Olga; Foschi, Matteo; Grand'Maison, Francois; John, Nevin; Grammond, Pierre; Terzi, Murat; Prévost, Julie; Barnett, Michael; Laureys, Guy; Van Hijfte, Liesbeth; Luis Sanchez-Menoyo, Jose; Blanco, Yolanda; Oh, Jiwon; McCombe, Pamela; Ramo Tello, Cristina; Soysal, Aysun; Prat, Alexandre; Duquette, Pierre; Yamout, Bassem I; Khoury, Samia; van Pesch, Vincent; Macdonell, Richard; José Sá, Maria; Slee, Mark; Kuhle, Jens; Maimone, Davide; Spitaleri, Daniele LA; Willekens, Barbara; Asmi, Abdallah Al; Tallantyre, Emma; Robertson, Neil P; Coles, Alasdair; L Brown, J William; Kalincik, Tomas.
Affiliation
  • Roos I; CORe, Department of Medicine, The University of Melbourne, Melbourne, VIC, Australia; Neuroimmunology Centre, Department of Neurology, The Royal Melbourne Hospital, Melbourne, VIC, Australia.
  • Sharmin S; CORe, Department of Medicine, The University of Melbourne, Melbourne, VIC, Australia; Neuroimmunology Centre, Department of Neurology, The Royal Melbourne Hospital, Melbourne, VIC, Australia.
  • Malpas C; CORe, Department of Medicine, The University of Melbourne, Melbourne, VIC, Australia; Neuroimmunology Centre, Department of Neurology, The Royal Melbourne Hospital, Melbourne, VIC, Australia.
  • Ozakbas S; Dokuz Eylul University, Konak, Izmir, Turkey.
  • Lechner-Scott J; Hunter Medical Research Institute, The University of Newcastle, Newcastle, NSW, Australia/John Hunter Hospital, Hunter New England Health, Newcastle, NSW, Australia.
  • Hodgkinson S; Immune Tolerance Laboratory Ingham Institute and Department of Medicine, UNSW, Sydney, NSW, Australia.
  • Alroughani R; Division of Neurology, Department of Medicine, Amiri Hospital, Sharq, Kuwait.
  • Eichau Madueño S; Hospital Universitario Virgen Macarena, Sevilla, Spain.
  • Boz C; Faculty of Medicine, Karadeniz Technical University, Trabzon, Turkey.
  • van der Walt A; Department of Neurology, The Alfred Hospital, Melbourne, VIC, Australia; Department of Neuroscience, Central Clinical School, Monash University, Melbourne, VIC, Australia.
  • Butzkueven H; Department of Neurology, The Alfred Hospital, Melbourne, VIC, Australia; Department of Neuroscience, Central Clinical School, Monash University, Melbourne, VIC, Australia.
  • Buzzard K; Neuroimmunology Centre, Department of Neurology, The Royal Melbourne Hospital, Melbourne, VIC, Australia.
  • Skibina O; Department of Neurology, Box Hill Hospital, Melbourne, VIC, Australia.
  • Foschi M; Department of Neurosciences, Eastern Health Clinical School, Monash University, Melbourne, VIC, Australia.
  • Grand'Maison F; Department of Neurology, The Alfred Hospital, Melbourne, VIC, Australia.
  • John N; Department of Neurology, Box Hill Hospital, Melbourne, VIC, Australia.
  • Grammond P; Department of Neurosciences, Eastern Health Clinical School, Monash University, Melbourne, VIC, Australia.
  • Terzi M; Department of Neuroscience, Multiple Sclerosis Center, S. Maria delle Croci Hospital of Ravenna, Ravenna, Italy.
  • Prévost J; Department of Biotechnological and Applied Clinical Sciences (DISCAB), University of L'Aquila, L'Aquila, Italy.
  • Barnett M; Neuro Rive-Sud, Greenfield Park, QC, Canada.
  • Laureys G; Department of Neurology, Monash Health, Melbourne, VIC, Australia.
  • Van Hijfte L; Department of Medicine, School of Clinical Sciences, Monash University, Clayton, VIC, Australia.
  • Luis Sanchez-Menoyo J; CISSS de Chaudière-Appalache, Sainte-Marie, QC, Canada.
  • Blanco Y; Faculty of Medicine, Ondokuz Mayis University, Samsun, Turkey.
  • Oh J; CSSS de Saint-Jérôme, Saint-Jerome, QC, Canada.
  • McCombe P; Brain and Mind Centre, Sydney, NSW, Australia.
  • Ramo Tello C; Department of Neurology, Ghent University Hospital, Ghent, Belgium.
  • Soysal A; Department of Neurology, Ghent University Hospital, Ghent, Belgium.
  • Prat A; Department of Neurology, Hospital de Galdakao-Usansolo, Biocruces-Bizkaia Health Research Institute, Galdakao, Spain.
  • Duquette P; Center of Neuroimmunology, Service of Neurology, Hospital Clinic de Barcelona, Barcelona, Spain.
  • Yamout BI; St. Michael's Hospital, Toronto, ON, Canada.
  • Khoury S; The University of Queensland, Brisbane, QLD, Australia; Royal Brisbane and Women's Hospital, Brisbane, OLD, Australia.
  • van Pesch V; Hospital Germans Trias i Pujol, Badalona, Spain.
  • Macdonell R; Bakirkoy Education and Research Hospital for Psychiatric and Neurological Diseases, Istanbul, Turkey.
  • José Sá M; CHUM MS Center and Universite de Montreal, Montreal, QC, Canada.
  • Slee M; CHUM MS Center and Universite de Montreal, Montreal, QC, Canada.
  • Kuhle J; Nehme and Therese Tohme Multiple Sclerosis Center, American University of Beirut Medical Center, Beirut, Lebanon.
  • Maimone D; Nehme and Therese Tohme Multiple Sclerosis Center, American University of Beirut Medical Center, Beirut, Lebanon.
  • Spitaleri D; Cliniques Universitaires Saint-Luc, Brussels, Belgium.
  • Willekens B; Austin Health, Melbourne, VIC, Australia.
  • Asmi AA; Department of Neurology, Centro Hospitalar Universitario de Sao Joao, Porto, Portugal; Faculty of Health Sciences, University Fernando Pessoa, Porto, Portugal.
  • Tallantyre E; College of Medicine and Public Health, Flinders University, Adelaide, Australia.
  • Robertson NP; Neurology, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Departments of Head, Spine and Neuromedicine, Biomedicine and Clinical Research, University Hospital Basel, Basel, Switzerland.
  • Coles A; Centro Sclerosi Multipla, UOC Neurologia, ARNAS Garibaldi, Catania, Italy.
  • L Brown JW; Azienda Ospedaliera di Rilievo Nazionale San Giuseppe Moscati Avellino, Avellino, Italy.
  • Kalincik T; Department of Neurology, Antwerp University Hospital, Edegem, Belgium.
Mult Scler ; 30(9): 1163-1175, 2024 Aug.
Article in En | MEDLINE | ID: mdl-39087208
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cladribine / Multiple Sclerosis, Relapsing-Remitting / Antibodies, Monoclonal, Humanized / Fingolimod Hydrochloride / Natalizumab / Alemtuzumab / Immunosuppressive Agents Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: Mult Scler Journal subject: NEUROLOGIA Year: 2024 Document type: Article Affiliation country: Australia Country of publication: Reino Unido
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cladribine / Multiple Sclerosis, Relapsing-Remitting / Antibodies, Monoclonal, Humanized / Fingolimod Hydrochloride / Natalizumab / Alemtuzumab / Immunosuppressive Agents Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: Mult Scler Journal subject: NEUROLOGIA Year: 2024 Document type: Article Affiliation country: Australia Country of publication: Reino Unido